Our study reveals that ILF3‐MRPL12 axis confers HCC cells drug resistance and ILF3 is a potential therapeutic target to overcome resistance, and lefamulin may be a novel combination therapy strategy for HCC treatment with TKIs. Here, MRPL12 is linked to hepatocellular carcinoma.